BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9730426)

  • 21. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
    Jonas S; Neuhaus R; Junge G; Klupp J; Theruvat T; Langrehr JM; Settmacher U; Neuhaus P
    Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy.
    Tang SC; Chan KW; Tang CS; Lam MF; Leung CY; Tse KC; Li CS; Ho YW; Tong MK; Lai KN; Chan TM;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3243-51. PubMed ID: 16877482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.
    Murphy GJ; Waller JR; Sandford RS; Furness PN; Nicholson ML
    Br J Surg; 2003 Jun; 90(6):680-6. PubMed ID: 12808614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression.
    Groetzner J; Kaczmarek I; Mueller M; Huber S; Deutsch A; Daebritz S; Arbogast H; Meiser B; Reichart B
    J Heart Lung Transplant; 2005 Nov; 24(11):1787-92. PubMed ID: 16297783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. European randomised trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients.
    Chang RW; Snowden S; Palmer A; Kwan JT; Nicholson M; Kashi SH; Fernando ON; Perner F; Neild GH
    Transpl Int; 2001 Dec; 14(6):384-90. PubMed ID: 11793035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO; Dias MF; Pacheco-Silva A
    Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients.
    Abou-Jaoude MM; Najm R; Shaheen J; Nawfal N; Abboud S; Alhabash M; Darwish M; Mulhem A; Ojjeh A; Almawi WY
    Transplant Proc; 2005 Sep; 37(7):3025-8. PubMed ID: 16213293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
    Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new rat infection-heart transplant model: effect of infection on graft survival studies.
    Kobayashi J; Mavroudis C; Crawford SE; Zales VR; Backer CL
    J Heart Lung Transplant; 1993; 12(4):659-64. PubMed ID: 7690253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
    J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.
    Tsamandas AC; Pham SM; Seaberg EC; Pappo O; Kormos RL; Kawai A; Griffith BP; Zeevi A; Duquesnoy R; Fung JJ; Starzl TE; Demetris AJ
    J Heart Lung Transplant; 1997 Jul; 16(7):723-34. PubMed ID: 9257254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats.
    Hisatomi K; Isomura T; Ohashi M; Tamehiro K; Sato T; Tayama E; Ohishi K; Kohjiro M
    J Heart Lung Transplant; 1995; 14(1 Pt 1):113-8. PubMed ID: 7537098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
    Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
    Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.
    Mayer AD; Dmitrewski J; Squifflet JP; Besse T; Grabensee B; Klein B; Eigler FW; Heemann U; Pichlmayr R; Behrend M; Vanrenterghem Y; Donck J; van Hooff J; Christiaans M; Morales JM; Andres A; Johnson RW; Short C; Buchholz B; Rehmert N; Land W; Schleibner S; Forsythe JL; Talbot D; Pohanka E
    Transplantation; 1997 Aug; 64(3):436-43. PubMed ID: 9275110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group.
    Klein A
    Liver Transpl Surg; 1999 Nov; 5(6):502-8. PubMed ID: 10545538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study.
    Arbustini E; Dal Bello B; Rinaldi M; Diegoli M; Grasso M; Pellegrini C; Morbini P; Martinelli L; Bonora MR; Viganò M
    J Heart Lung Transplant; 1997 Sep; 16(9):982-4. PubMed ID: 9322152
    [No Abstract]   [Full Text] [Related]  

  • 40. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group.
    Mentzer RM; Jahania MS; Lasley RD
    Transplantation; 1998 Jan; 65(1):109-13. PubMed ID: 9448154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.